舒尼替尼治疗转移性肾细胞癌的预算影响分析  

Budget Impact Analysis on Using Sunitinib for Metastatic Renal Carcinoma

作　　者：殷潇[1] 方欣[1] 胡江蔺 田梦媛 张欲晓[1] 崔丹[1] 毛宗福[1] 

机构地区：[1]武汉大学公共卫生学院,武汉430071

出　　处：《中国卫生经济》2016年第12期67-69,共3页Chinese Health Economics

摘　　要：目的:通过对舒尼替尼进行预算影响分析,为药品报销目录的遴选决策制定提供科学依据。方法:构建预算影响分析模型,测算舒尼替尼在进入医保目录之后对医保支出的预期影响。结果:如果2015年舒尼替尼进入城镇医保目录,2015到2019年m RCC患者医保预算总费用较前一年的增幅分别为18.5%、23.1%、27.8%、32.4%和37.0%。结论:将舒尼替尼纳入城镇医保增加医保预算费用,增幅和各变量呈线性相关。Objective： To conduct budget impact analysis on Sunitinib so as to provide references for its reimbursement policy on Urban Medical Insurance Plan. Methods： Budget impact analysis model was constructed to measure the expected changes in the ex- penditure of medical insurance system after Sunitinib was introduced in medical insurance list. Results： If Sunitinib could be reim- bursed since 2015, the increase rate of medical insurance budget on metastatic renal carcinoma（mRCC） patient in 2015-2019 would be 18.5%, 23.1%, 27.8%, 32.4% and 37.0%. Conclusion： Reimbursement of Sunitinib would increase the total budget of medical in- surance, and linear correlation was found between increase rate and variables.

关 键 词：转移性肾细胞癌 靶向药物 舒尼替尼 预算影响分析 

分 类 号：R737.11[医药卫生—肿瘤]